Myocardial No-reflow treatment

Current Vascular Pharmacology

Volumn 11, Issue 2, 2013, Pages 278-285

  Muller, Olivier ^a   Trana, Catalina ^a   Eeckhout, Eric ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Myocardial infarction; No reflow; Reperfusion; Slow flow

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENALIN; ATRIAL NATRIURETIC FACTOR; CREATINE KINASE; CYCLOSPORIN; DIPYRIDAMOLE; NICORANDIL; NITROPRUSSIDE SODIUM; PLACEBO; SODIUM CHLORIDE; TROPONIN I; VERAPAMIL; CARDIOVASCULAR AGENT;

ALGORITHM; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CONTRAST ECHOCARDIOGRAPHY; HEART INFARCTION; HUMAN; HYPERBARIC OXYGEN; INTRAAORTIC BALLOON PUMP; ISCHEMIC POSTCONDITIONING; META ANALYSIS (TOPIC); MICROCIRCULATION; NO REFLOW PHENOMENON; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; HUMANS; ISCHEMIC POSTCONDITIONING; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; TREATMENT OUTCOME;

EID: 84875330642     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113805290236     Document Type: Review

References (55)

1. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
2. Matsuo H, Watanabe S, Watanabe T, Warita S, Kojima T, Hirose T, Iwama M, Ono K, Takahashi H, Segawa T, Minatoguchi S, Fujiwara H. Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. Am Heart J 2007;154:994 e991-996.
3. Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, Kakarala V, Cohen AM, Marmur JD, Ambrose JA. Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol 1997;80:219-222.
4. Iwasaki K, Samukawa M, Furukawa H. Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. Am J Cardiol 2006;98:1354-1356.
5. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: Comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
6. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim DH, Kloostra A. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-365.
7. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: Again prevention is better than treatment. Eur Heart J 2010;31:2449-2455.
8. Niccoli G, Marino M, Spaziani C, Crea F. Prevention and treatment of no-reflow. Acute Card Care 2010;12:81-91.
9. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004;109:1121-1126.
10. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the timi myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002;105:1909-1913.
11. Muller O, Windecker S, Cuisset T, et al. Management of two major complications in the cardiac catheterisation laboratory: The noreflow phenomenon and coronary perforations. EuroIntervention 2008;4:181-183.
12. Kern MJ. Adenosine boluses: A cure for "no-reflow"? Cathet Cardiovasc Diagn 1998;45:366-367.
13. Granger CB. Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol 1997;79:44-48.
14. Alfayoumi F, Srinivasan V, Geller M, Gradman A. The no-reflow phenomenon: Epidemiology, pathophysiology, and therapeutic approach. Rev Cardiovasc Med 2005;6:72-83.
15. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The acute myocardial infarction study of adenosine (amistad) trial. J Am Coll Cardiol 1999;34:1711-1720.
16. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (amistad-ii). J Am Coll Cardiol 2005;45:1775-1780.
17. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: The amistad-2 trial. Eur Heart J 2006;27:2400-2405.
18. Micari A, Belcik TA, Balcells EA, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol 2005;96:1410-1415.
19. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary pci: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv 2008;71:283-289.
20. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-2159.
21. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute st-segment elevation myocardial infarction. Eur Heart J 2011;32:867-877.
22. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 1991;68:847-855.
23. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004;109:1236-1243.
24. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. J Am Coll Cardiol 2001;37:1335-1343.
25. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/noreflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004;63:171-176.
26. Airoldi F, Briguori C, Cianflone D, et al. Frequency of slow coronary flow following successful stent implantation and effect of nitroprusside. Am J Cardiol 2007;99:916-920.
27. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006;152:887 e889-814.
28. Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J 2007;48:423-433.
29. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004;61:484-491.
30. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: A clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 2007;85:476-482.
31. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-1199.
32. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444-451.
33. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000;12:80-85.
34. Tanzilli G, Greco C, Pasceri V, et al. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. Catheter Cardiovasc Interv 2010;76:787-793.
35. Mizumura T, Nithipatikom K, Gross GJ. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc Res 1995;29:482-489.
36. Klein HH, Pich S, Lindert-Heimberg S, Schade-Brittinger C, Maisch B, Nebendahl K. Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine hearts. Eur Heart J 1995;16:603-609.
37. Galie N, Guarnieri C, Ussia GP, et al. Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs. J Cardiovasc Pharmacol 1995;26:477-484.
38. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999;33:654-660.
39. Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004;148:E15.
40. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (j-wind): Two randomised trials. Lancet 2007;370:1483-1493.
41. Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002;57:305-309.
42. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
43. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: A systematic approach. JACC Cardiovasc Interv 2010;3:695-704.
44. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv 2000;51:394-399.
45. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the european society of cardiology (esc) and the european association for cardio-thoracic surgery (eacts). Eur Heart J 2010;31:2501-2555.
46. Maekawa K, Kawamoto K, Fuke S, et al. Effects of intraaortic balloon pumping on the angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with anterior myocardial infarction. Circ J 2006;70:37-43.
47. Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in st-elevation myocardial infarction: Should we change the guidelines? Eur Heart J 2009;30:459-468.
48. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112:2143-2148.
49. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008;117:1037-1044.
50. Cameron AJ, Hutton I, Kenmure AC, Murdoch WR. Haemodynamic and metabolic effects of hyperbaric oxygen in myocardial infarction. Lancet 1966;2:833-837.
51. Sterling DL, Thornton JD, Swafford A, et al. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. Circulation 1993;88:1931-1936.
52. Thomas MP, Brown LA, Sponseller DR, Williamson SE, Diaz JA, Guyton DP. Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator. Am Heart J 1990;120:791-800.
53. Glazier JJ. Attenuation of reperfusion microvascular ischemia by aqueous oxygen: Experimental and clinical observations. Am Heart J 2005;149:580-584.
54. Trabattoni D, Bartorelli AL, Fabbiocchi F, et al. Hyperoxemic perfusion of the left anterior descending coronary artery after primary angioplasty in anterior st-elevation myocardial infarction. Catheter Cardiovasc Interv 2006;67:859-865.
55. O'Neill WW, Martin JL, Dixon SR, et al. Acute myocardial infarction with hyperoxemic therapy (amihot): A prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:397-405.